You seem to be using a wider screen, would you like to enable a wider viewing experience on this page?
Eltel Q3´24: Progress is evident but still lot of room for improvement
Eltel released the Q3 report today and while the adjusted EBITDA was impressive, there’s still significant work ahead to maintain and build on these improvements. Eltel´s CEO Håkan Dahlström summarizes the third quarter, elaborates regarding the demand and outlook situation and why they removed the timeframe of their financial targets.
00:00 Introduction
00:18 Q3 key takeaways
00:41 Norway situation
01:34 Finland & Sweden
02:23 Demand & outlook
03:49 Competition
04:09 Renewable energy’s outlook
04:38 Strategy execution
05:25 Removed timeframe for financial targets
Herantis Pharma as an Investment | Life Science Night Dec. 2, 2024
Aiforia as an Investment | Life Science Night Dec. 2, 2024
Faron Pharmaceuticals as an Investment | Life Science Night Dec. 2, 2024
Life Science Companies as Investments | Life Science Night Dec. 2, 2024
Life Science Night | December 2, 2024
Titta på alla videor